Details of the Drug Pharmacogenomic Perturbation Atlas

Etomidate Drug Info

Absele; Amidate; Ethnor; Ethomidate; Etomidato; Etomidatum; Hypnomidate; Radenarcon; Radenarkon; Etomidic acid; R 16659; R 26490; R26490; Amidate (TN); Amidate (pharmaceutical); Amidate, Etomidate; D-Etomidate; Etomidato [INN-Spanish]; Etomidatum [INN-Latin]; R-26490; Etomidate (USAN/INN); Etomidate [USAN:BAN:INN]; Ethyl 3-(1-phenylethyl)imidazole-4-carboxylate; Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; (+)-Etomidate; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; (d)-Etomidate; 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester

Therapeutic Class

Analgesics

Cross-matching ID

PubChem CID

667484

ChEBI ID

CHEMBL681

CAS Number

CAS 33125-97-2

TTD Drug ID

D02YPG

ACDINA Drug ID

D01065

General Information of Drug (ID: DMZI3WO)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	1.80	1.04e-1	34/36 (94.44%)	PCNA;POLE2;PRIM1;...
Cell cycle	1.74	8.34e-2	110/124 (88.71%)	PCNA;CDC20;PLK1;...
Ribosome biogenesis in eukaryotes	1.73	6.02e-2	52/108 (48.15%)	NXT1;RAN;RPP40;...
Primary bile acid biosynthesis	1.70	7.12e-2	15/17 (88.24%)	CH25H;CYP39A1;CYP27A1;...
Proximal tubule bicarbonate reclamation	1.69	6.12e-2	21/23 (91.3%)	CA2;SLC4A4;AQP1
Spliceosome	1.68	5.68e-2	101/150 (67.33%)	PUF60;HSPA8;LSM5;...
Phototransduction	1.65	6.55e-2	21/29 (72.41%)	CALML5;CALML3
Oxidative phosphorylation	1.56	1.37e-1	93/133 (69.92%)	CYC1;ATP5F1C;COX7B;...
Terpenoid backbone biosynthesis	1.54	1.54e-1	18/22 (81.82%)	IDI1;ACAT2;PCYOX1;...
Bile secretion	1.54	1.42e-1	68/90 (75.56%)	CA2;UGT2B28;SLC4A4;...
Caffeine metabolism	1.52	1.60e-1	5/6 (83.33%)	NAT2;CYP1A2;NAT1;...
Protein export	1.50	1.78e-1	17/23 (73.91%)	SPCS3;SRPRB;SRP9;...
Prion disease	1.49	1.72e-1	209/273 (76.56%)	HSPA8;PPIF;C7;...
Progesterone-mediated oocyte maturation	1.47	2.02e-1	75/100 (75%)	PLK1;STK10;CCNB1;...
Mismatch repair	1.46	2.01e-1	22/23 (95.65%)	PCNA;RFC4;MLH1;...
Folate biosynthesis	1.45	1.96e-1	23/26 (88.46%)	GGH;PTS;PAH;...
Proteasome	1.43	2.17e-1	44/46 (95.65%)	PSMB10;PSMC6;PSMD14;...
Pyrimidine metabolism	1.43	2.14e-1	40/56 (71.43%)	TYMS;DPYS;DCTPP1;...
Malaria	1.42	2.14e-1	44/50 (88%)	CD40;THBS2;THBS1;...
Base excision repair	1.41	2.16e-1	29/33 (87.88%)	PCNA;POLE2;FEN1;...
Metabolism of xenobiotics by cytochrome P450	1.40	2.22e-1	49/77 (63.64%)	UGT2B28;HSD11B1;GSTT1;...
PPAR signaling pathway	1.39	2.37e-1	66/74 (89.19%)	FABP7;FABP5;ACSBG1;...
One carbon pool by folate	1.37	2.52e-1	15/20 (75%)	TYMS;DHFR;ATIC;...
Thiamine metabolism	1.37	2.43e-1	12/15 (80%)	AK4;ALPL;AK5
Ubiquinone and other terpenoid-quinone biosynthesis	1.36	2.64e-1	9/11 (81.82%)	COQ3;HPD
Drug metabolism	1.36	2.55e-1	78/151 (51.66%)	UGT2B28;GSTT1;DPYS;...
Arachidonic acid metabolism	1.35	2.58e-1	48/61 (78.69%)	CYP2J2;PTGIS;GPX3;...
Vitamin digestion and absorption	1.34	2.64e-1	17/24 (70.83%)	APOA1;LMBRD1;MMACHC;...
RNA transport	1.33	2.84e-1	128/186 (68.82%)	NUP85;NXT1;RAN;...
Synthesis and degradation of ketone bodies	1.32	2.75e-1	9/10 (90%)	ACAT2;BDH2;HMGCS2;...
Adipocytokine signaling pathway	-1.45	1.35e-1	64/69 (92.75%)	ACSL5;ACSBG2;ACSL4;...
Ether lipid metabolism	-1.45	1.33e-1	32/49 (65.31%)	PLA2G2A;PLA2G6;PLA2G7;...
Tight junction	-1.46	1.36e-1	130/169 (76.92%)	TJP1;JAM2;LLGL1;...
Pancreatic cancer	-1.46	1.37e-1	75/76 (98.68%)	ARHGEF6;RPS6KB1;BAK1;...
Autophagy	-1.47	1.36e-1	113/169 (66.86%)	TSC2;ATG14;ATG9A;...
Thyroid hormone signaling pathway	-1.49	1.29e-1	112/121 (92.56%)	PLCD1;FXYD2;ATP1A1;...
Apelin signaling pathway	-1.49	1.32e-1	117/137 (85.4%)	JAG1;CDH1;RPS6KB1;...
NOD-like receptor signaling pathway	-1.49	1.36e-1	145/181 (80.11%)	IL6;JUN;MFN2;...
Transcriptional misregulation in cancer	-1.49	1.36e-1	158/192 (82.29%)	AFF1;BAK1;TFE3;...
Amino sugar and nucleotide sugar metabolism	-1.51	1.32e-1	38/48 (79.17%)	HK3;GMPPA;PMM2;...
Growth hormone synthesis, secretion and action	-1.51	1.38e-1	108/119 (90.76%)	ADCY1;STAT1;PLCG1;...
Endometrial cancer	-1.53	1.30e-1	56/58 (96.55%)	MAPK3;AKT1;CTNNA1;...
Cushing syndrome	-1.53	1.37e-1	125/155 (80.65%)	DVL1;ADCY6;DVL2;...
Graft-versus-host disease	-1.54	1.36e-1	32/42 (76.19%)	HLA-DRB1;HLA-DPB1;HLA-G;...
PI3K-Akt signaling pathway	-1.55	1.31e-1	317/354 (89.55%)	CDC37;IL4R;GNG7;...
Human papillomavirus infection	-1.56	1.29e-1	284/331 (85.8%)	CHD4;COL2A1;PRKCZ;...
Pentose phosphate pathway	-1.57	1.14e-1	25/30 (83.33%)	GPI;TKTL1;TKT;...
Mitophagy	-1.57	1.19e-1	56/68 (82.35%)	ATG9A;NBR1;BNIP3;...
MicroRNAs in cancer	-1.58	1.21e-1	146/310 (47.1%)	PLCG1;PLAU;NOTCH3;...
AMPK signaling pathway	-1.61	1.04e-1	106/120 (88.33%)	TSC2;PPP2R5B;PPARG;...
Amoebiasis	-1.61	1.14e-1	99/102 (97.06%)	ADCY1;PRKCA;COL1A1;...
Other glycan degradation	-1.62	1.21e-1	13/18 (72.22%)	MAN2B2;NEU1;MAN2B1;...
Non-small cell lung cancer	-1.62	1.34e-1	70/72 (97.22%)	BAK1;PLCG1;PRKCA;...
Proteoglycans in cancer	-1.65	1.26e-1	172/205 (83.9%)	MDM2;FGFR1;ROCK1;...
Type II diabetes mellitus	-1.66	1.23e-1	42/46 (91.3%)	MTOR;HKDC1;PRKCZ;...
Kaposi sarcoma-associated herpesvirus infection	-1.68	1.23e-1	172/193 (89.12%)	GNG7;IL6;JUN;...
Bacterial invasion of epithelial cells	-1.72	9.94e-2	59/77 (76.62%)	CDH1;DNM2;CLTCL1;...
Focal adhesion	-1.75	9.07e-2	180/201 (89.55%)	PAK5;PPP1CB;DIAPH1;...
Viral myocarditis	-1.75	1.21e-1	53/60 (88.33%)	HLA-G;ABL1;CASP9;...
Small cell lung cancer	-1.84	1.34e-1	90/92 (97.83%)	AKT1;FN1;COL4A1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 2.22uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H